Cross-sectional study shows coupons may facilitate product hopping in pharmaceuticals, suggesting regulatory monitoring is needed.
In this cross-sectional study, manufacturer coupon use for candidate hop biologics diverged from comparators as originators neared exclusivity loss, suggesting coupons may facilitate product hopping. Regulators should consider monitoring coupon programs during biologic exclusivity transitions.
No takes yet. Share an insight, caveat, or question.
Gibbons et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: